Theme

Field-oriented
sessions

Session Title

Immunotherapy

PresentationNo.

AbstractNo.

Lecture title

SpeakerCountry

IMM-IS-01

IS-15

Advances in cellular immunotherapy targeting pediatric brain tumors

Duane MitchellUSA

IMM-IS-02

IS-16

Today's immunotherapy for pediatric CNS tumors: briefly defining the Gordian Knot

Eugene Hwang

USA

IMM-IS-03

SPKR-12Nivolumab monotherapy and nivolumab in combination with ipilimumab in pediatricpatients with high-grade primary central nervous system malignancies: safety andpharmacokinetic results from CheckMate 908

Ira Dunkel

USA

IMM-QA-04-Panel discussion/Q&A

Panel discussion/Q&A

IMM-O-05

IMMU-31

PNOC007: H3.3K27M Specific peptide vaccine combined with poly-ICLC for thetreatment of newly diagnosed HLA-A2+ H3.3K27M Diffuse Midline Gliomas (DMG)

Sabine Mueller

USAIMM-O-06

IMMU-13

Dual IGF1R/IR inhibitor in combination with GD2-CAR T-cells as a potent therapeuticstrategy for H3K27M-mutant diffuse midline gliomas

Emmanuel de Billy

Italy

IMM-O-07

IMMU-18

Favorable outcome in replication repair deficient hypermutant brain tumors to immune
checkpoint inhibition: An international RRD consortium registry study

Sumedha Sudhaman

CanadaIMM-P-08

IMMU-08

reMATCH protocol: Phase II study of ex-vivo expanded autologous tumor specificlymphocyte transfer (x-ALT) + total tumor RNA DC vaccine (tt-RNA DC) during recovery
from myeloablative chemotherapy (MAC) and peripheral blood stem cell (PBSC) rescue Sridharan Gururanganor non-myeloablative chemotherapy (NMAC) and PBSC in patients (pts) with recurrent
PNET (r-PNET)

USAIMM-P-09

IMMU-06

T-cell immunotherapy for pediatric brain tumors: diversity in cell surface antigen andHLA expression necessitates a multi-pronged approach

Haley Houke

USAIMM-P-10

IMMU-10

Interim analysis of the HIT-HGG Rez Immunvac study - Dendritic cell vaccination withpartial Treg depletion in children, adolescents, and adults with relapsed high-grade
gliomasMatthias Eyrich

Germany

IMM-P-11

IMMU-22

Phase Ib Immunotherapy clinical trial with the use of autologous dendritic cells pulsedwith an allogenic tumoral cell lines lysate in patients with newly diagnosed diffuse
intrinsic pontine glioma (DIPG)

Andres Morales La MadridSpain

IMM-P-12

IMMU-23

A novel mass cytometry-based multi-parameter characterization of neoantigen-reactiveTakahide Nejo
CD8+ T-cells in patients participating in PNOC007 H3.3K27M peptide vaccine clinical
trial

USA

IMM-P-13

IMMU-12Phase I/II trial of immunotherapy with fusions of dendritic cells and tumor cells forrelapsed or refractory brain tumors in children and young adults

JapanIMM-P-14

IMMU-03

Updates on BrainChild-01, -02, and -03: phase 1 locoregional CAR T cell trials targeting
Nicholas Vitanza
HER2, EGFR, and B7-H3 for children with recurrent CNS tumors and DIPG

USAIMM-P-15

IMMU-05

B7-H3-specific CAR T cells have potent anti-tumor activity in the GL261 immunecompetent murine brain tumor model

Dalia Haydar

USA

IMM-P-17

IMMU-15

Proteogenomic discovery of novel tumor peptides as neoantigens for personalized Tcell immunotherapy in medulloblastoma

Brian RoodUSA

IMM-P-18

IMMU-30

Upregulated T cell and interferon-γ-related gene expression is associated withincreased survival in recurrent pediatric high-grade glioma

Tom DavidsonUSAIMM-P-19

IMMU-02

Chimeric antigen receptor (CAR) T cell neurotoxicity correlates with pretreatment andacute CSF neurofilament light chain (NFL) levels

Juliane GustUSA

IMM-P-20

IMMU-16

Intra-tumoural IL-12 delivery enables CAR T-cell immunotherapy for high-grade glioma Karin Straathof

UK

IMM-P-21

IMMU-17

CAR T cells targeting the integrin alphavbeta3 exhibit robust anti-tumor responses
against diffuse intrinsic pontine glioma (DIPG) and glioblastoma (GBM)

Dustin Cobb

USA

IMM-P-22

IMMU-11

Locoregional delivery of transient GD2 CAR T cells for safe and effective treatment ofDIPG

Jessica Foster

USA

IMM-P-23

IMMU-20

Evaluation of CAR T cells in ependymoma

Anandani Nellan

USA

IMM-P-24

IMMU-19

HDAC inhibitors sensitize MYC-amplified Medulloblastoma to Immunotherapy byactivating the NF-kB Pathways

Siddhartha Mitra

USA

IMM-P-25

IMMU-21

Investigation of white blood cell characteristics in CSF samples at pediatric brain tumor
Adam Green
diagnosis

USA

IMM-P-26

IMMU-14

Immune checkpoint inhibitor therapy for treatment of synchronous cancers in paediatric
Jacob Hendersonpatients with constitutional mismatch repair deficiency

USAIMM-P-27

IMMU-01

Immune checkpoint inhibition for pediatric CNS tumors: A single institution experience

Chantel Cacciotti

USA

IMM-P-28

IMMU-27

Analysis of immune signatures in pediatric glioblastomas for patient stratification toimmunotherapy

Vidya Chandramohan

USA

IMM-P-29

IMMU-29

AIF1 is a prognostic biomarker and correlated with immune infiltrates in gliomas

Yi Chai

China

IMM-P-30

IMMU-26

Disease control in a pediatric patient with newly diagnosed glioblastoma multiforme(GBM) and somatic high microsatellite instability (MSI-H) with PD-1 inhibitor Nivolumab Trisha Larkin(NIVO) only and no focal radiotherapy (RT)

USAIMM-P-31

IMMU-28

Immunogenomic analysis reveals LGALS1 contributes to the immune heterogeneityand immunosuppression in glioma

Qun Chen

China

IMM-P-32

IMMU-09

NIVOLUMAB therapy for a pediatric-onset primary intracranial melanoma

Utako ObaJapan

IMM-P-33

IMMU-07

Immune Effector Cell Associated Neurotoxicity (ICANS) among pediatric and AYA
patients:MD Anderson Cancer Center experience

Brandon Brown

USAMasayoshi Yamaoka